Nurix Therapeutics (NRIX)
Nurix Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
17.7M
Short interest
settlement 2026-09-30
9.9
Days to cover
-4.1 days vs prior
53.7%
Short share of volume
2026-10-23
47
Fails to deliver
settlement 2026-09-02
Wed 27 Jan
Next earnings
estimated date
-$1.8M
Insider flow, 90 days
0 buys, 15 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in NRIX is 17,657,588 shares, down 292,873 shares over the last month. Over the last 48 readings it ranged from 9,240,563 shares (15 October 2024) to 20,024,913 shares (15 June 2026). At the reported average volume of 1.8M shares a day that is 9.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/nrix" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 17,657,588 | -1.8% | 1,776,243 | 9.94 |
| 2026-09-15 | 17,976,804 | +0.1% | 1,279,919 | 14.05 |
| 2026-08-31 | 17,950,461 | -0.2% | 1,126,118 | 15.94 |
| 2026-08-14 | 17,984,342 | -2.0% | 993,103 | 18.11 |
| 2026-07-31 | 18,351,438 | +2.1% | 1,019,972 | 17.99 |
| 2026-07-15 | 17,979,165 | +1.0% | 1,296,203 | 13.87 |
| 2026-06-30 | 17,798,300 | -11.1% | 3,279,006 | 5.43 |
| 2026-06-15 | 20,024,913 | +3.6% | 4,050,135 | 4.94 |
| 2026-05-29 | 19,321,862 | +3.7% | 1,298,393 | 14.88 |
| 2026-05-15 | 18,633,310 | -3.0% | 838,931 | 22.21 |
| 2026-04-30 | 19,201,109 | +0.0% | 789,342 | 24.33 |
| 2026-04-15 | 19,201,724 | +5.9% | 1,364,154 | 14.08 |
| 2026-03-31 | 18,130,036 | +12.1% | 1,569,882 | 11.55 |
| 2026-03-13 | 16,178,402 | +1.3% | 825,157 | 19.61 |
| 2026-02-27 | 15,971,376 | +4.7% | 787,247 | 20.29 |
| 2026-02-13 | 15,248,252 | +1.9% | 847,584 | 17.99 |
| 2026-01-30 | 14,961,980 | -1.6% | 1,276,463 | 11.72 |
| 2026-01-15 | 15,197,058 | +3.8% | 1,380,737 | 11.01 |
| 2025-12-31 | 14,644,521 | +7.3% | 1,559,025 | 9.39 |
| 2025-12-15 | 13,642,687 | -5.8% | 2,207,900 | 6.18 |
| 2025-11-28 | 14,487,622 | +2.9% | 1,591,416 | 9.10 |
| 2025-11-14 | 14,076,725 | +7.3% | 1,468,931 | 9.58 |
| 2025-10-31 | 13,118,235 | -5.4% | 2,176,479 | 6.03 |
| 2025-10-15 | 13,868,490 | +6.4% | 1,415,573 | 9.80 |
| 2025-09-30 | 13,035,274 | -0.1% | 1,174,571 | 11.10 |
| 2025-09-15 | 13,045,894 | +1.9% | 857,974 | 15.21 |
| 2025-08-29 | 12,809,274 | -0.5% | 789,439 | 16.23 |
| 2025-08-15 | 12,876,254 | -1.2% | 548,248 | 23.49 |
| 2025-07-31 | 13,033,202 | -6.5% | 802,817 | 16.23 |
| 2025-07-15 | 13,946,880 | -0.8% | 1,178,586 | 11.83 |
| 2025-06-30 | 14,066,887 | -2.5% | 764,713 | 18.39 |
| 2025-06-13 | 14,435,008 | +2.5% | 977,625 | 14.77 |
| 2025-05-30 | 14,088,045 | -0.2% | 770,715 | 18.28 |
| 2025-05-15 | 14,116,491 | +3.1% | 710,602 | 19.87 |
| 2025-04-30 | 13,689,680 | -4.8% | 1,072,034 | 12.77 |
| 2025-04-15 | 14,387,338 | +18.3% | 1,372,582 | 10.48 |
| 2025-03-31 | 12,159,893 | -0.1% | 998,470 | 12.18 |
| 2025-03-14 | 12,168,982 | +4.9% | 860,161 | 14.15 |
| 2025-02-28 | 11,596,188 | +2.1% | 782,772 | 14.81 |
| 2025-02-14 | 11,361,295 | +3.8% | 681,713 | 16.67 |
| 2025-01-31 | 10,948,051 | +0.8% | 594,222 | 18.42 |
| 2025-01-15 | 10,865,940 | +0.7% | 740,861 | 14.67 |
| 2024-12-31 | 10,793,866 | +9.8% | 894,430 | 12.07 |
| 2024-12-13 | 9,830,540 | +5.2% | 924,136 | 10.64 |
| 2024-11-29 | 9,346,993 | -2.7% | 882,395 | 10.59 |
| 2024-11-15 | 9,603,933 | +1.5% | 1,234,226 | 7.78 |
| 2024-10-31 | 9,457,834 | +2.4% | 739,789 | 12.78 |
| 2024-10-15 | 9,240,563 | +1.8% | 926,972 | 9.97 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of NRIX volume is 53.7%, down 0.6 points over the last five sessions. Over the last 30 readings it ranged from 27.9% (20 October 2026) to 63.8% (5 October 2026). The latest reading is 5.5 points above the 30-session average of 48.3%, on 587K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 315K | 587K | 53.7% | 51 |
| 2026-10-22 | 302K | 611K | 49.5% | 50 |
| 2026-10-21 | 328K | 942K | 34.8% | 0 |
| 2026-10-20 | 436K | 1.6M | 27.9% | 0 |
| 2026-10-19 | 466K | 1.2M | 38.5% | 2,950 |
| 2026-10-16 | 615K | 1.1M | 54.4% | 0 |
| 2026-10-15 | 479K | 1.2M | 40.9% | 1,144 |
| 2026-10-14 | 635K | 1.1M | 57.1% | 17,684 |
| 2026-10-13 | 741K | 1.3M | 58.7% | 5,377 |
| 2026-10-12 | 266K | 579K | 46.0% | 0 |
| 2026-10-09 | 222K | 510K | 43.5% | 0 |
| 2026-10-08 | 430K | 773K | 55.6% | 80 |
| 2026-10-07 | 294K | 600K | 49.0% | 0 |
| 2026-10-06 | 216K | 419K | 51.6% | 0 |
| 2026-10-05 | 149K | 234K | 63.8% | 0 |
| 2026-10-02 | 162K | 271K | 59.8% | 0 |
| 2026-10-01 | 161K | 307K | 52.4% | 0 |
| 2026-09-30 | 202K | 430K | 47.1% | 200 |
| 2026-09-29 | 187K | 527K | 35.4% | 0 |
| 2026-09-28 | 204K | 491K | 41.5% | 824 |
| 2026-09-25 | 216K | 444K | 48.7% | 0 |
| 2026-09-24 | 282K | 780K | 36.1% | 2 |
| 2026-09-23 | 232K | 471K | 49.3% | 72 |
| 2026-09-22 | 288K | 599K | 48.1% | 0 |
| 2026-09-21 | 278K | 478K | 58.3% | 822 |
| 2026-09-18 | 340K | 766K | 44.3% | 0 |
| 2026-09-17 | 400K | 707K | 56.6% | 0 |
| 2026-09-16 | 205K | 411K | 49.8% | 1,412 |
| 2026-09-15 | 244K | 504K | 48.3% | 0 |
| 2026-09-14 | 220K | 466K | 47.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 2 September 2026, the fails-to-deliver balance in NRIX is 47 shares, down 133 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (22 May 2026) to 70,287 shares (26 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-02 | 47 | $26.04 | $1K |
| 2026-08-17 | 180 | $27.05 | $5K |
| 2026-08-14 | 67 | $27.19 | $2K |
| 2026-08-06 | 2,997 | $25.12 | $75K |
| 2026-07-22 | 4 | $23.48 | $94 |
| 2026-07-20 | 11,461 | $23.12 | $265K |
| 2026-07-06 | 200 | $23.97 | $5K |
| 2026-07-02 | 177 | $23.91 | $4K |
| 2026-07-01 | 493 | $24.26 | $12K |
| 2026-06-30 | 100 | $23.85 | $2K |
| 2026-06-29 | 3,848 | $22.90 | $88K |
| 2026-06-26 | 70,287 | $22.46 | $1.6M |
| 2026-06-25 | 90 | $19.30 | $2K |
| 2026-06-24 | 11 | $18.86 | $207 |
| 2026-06-23 | 21 | $18.65 | $392 |
| 2026-06-18 | 61 | $17.12 | $1K |
| 2026-06-15 | 6,325 | $16.95 | $107K |
| 2026-06-12 | 619 | $16.98 | $11K |
| 2026-06-05 | 158 | $15.28 | $2K |
| 2026-06-01 | 893 | $17.76 | $16K |
| 2026-05-29 | 510 | $17.67 | $9K |
| 2026-05-28 | 194 | $17.47 | $3K |
| 2026-05-26 | 1,232 | $17.50 | $22K |
| 2026-05-22 | 4 | $17.53 | $70 |
| 2026-05-19 | 136 | $15.51 | $2K |
| 2026-05-13 | 7,133 | $15.96 | $114K |
| 2026-05-06 | 743 | $16.60 | $12K |
| 2026-05-05 | 743 | $16.93 | $13K |
| 2026-04-27 | 138 | $16.68 | $2K |
| 2026-04-20 | 12,832 | $17.51 | $225K |
Insider trades
SEC Form 4, newest first. JSONInsiders at NRIX reported 15 open-market sells worth $1.8M in the last 90 days and no open-market buys. Latest filing: Hansen Gwenn (Chief Scientific Officer) on 2026-10-15.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Hansen Gwenn | Chief Scientific Officer | Sell | 1K | $25.00 | $36K | 117K |
| 2026-10-15 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 1K | $1.86 | $3K | 119K |
| 2026-10-14 | GREGORY JULIA P | Director | Sell | 23K | $23.40 | $529K | 11K |
| 2026-10-14 | GREGORY JULIA P | Director | Exercise or conversion | 23K | $1.86 | $42K | 33K |
| 2026-10-02 | Ring Christine | Chief Legal Officer | Sell | 6K | $23.19 | $134K | 9K |
| 2026-10-02 | Ring Christine | Chief Legal Officer | Exercise or conversion | 6K | $8.72 | $50K | 15K |
| 2026-09-02 | Ring Christine | Chief Legal Officer | Sell | 400 | $26.64 | $11K | 9K |
| 2026-09-02 | Ring Christine | Chief Legal Officer | Sell | 5K | $25.69 | $138K | 10K |
| 2026-09-02 | Ring Christine | Chief Legal Officer | Exercise or conversion | 6K | $8.72 | $50K | 15K |
| 2026-09-01 | Hansen Gwenn | Chief Scientific Officer | Sell | 1K | $25.47 | $37K | 117K |
| 2026-09-01 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 1K | $1.86 | $3K | 119K |
| 2026-08-05 | Hansen Gwenn | Chief Scientific Officer | Sell | 4K | $25.00 | $109K | 117K |
| 2026-08-05 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 4K | $1.86 | $8K | 122K |
| 2026-08-04 | Hansen Gwenn | Chief Scientific Officer | Sell | 3K | $24.64 | $64K | 117K |
| 2026-08-04 | Hansen Gwenn | Chief Scientific Officer | Sell | 2K | $23.87 | $36K | 120K |
| 2026-08-04 | van Houte Hans | Chief Financial Officer | Sell | 3K | $24.65 | $73K | 40K |
| 2026-08-04 | van Houte Hans | Chief Financial Officer | Sell | 2K | $23.89 | $43K | 43K |
| 2026-08-03 | Ring Christine | Chief Legal Officer | Sell | 17K | $23.05 | $382K | 9K |
| 2026-08-03 | Ring Christine | Chief Legal Officer | Exercise or conversion | 6K | $8.72 | $50K | 26K |
| 2026-07-30 | van Houte Hans | Chief Financial Officer | Sell | 3K | $23.38 | $67K | 45K |
| 2026-07-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 4K | $0.00 | $0 | 48K |
| 2026-07-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 3K | $0.00 | $0 | 44K |
| 2026-07-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 4K | $0.00 | $0 | 41K |
| 2026-07-30 | Ring Christine | Chief Legal Officer | Sell | 4K | $23.38 | $90K | 20K |
| 2026-07-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 4K | $0.00 | $0 | 24K |
| 2026-07-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 3K | $0.00 | $0 | 20K |
| 2026-07-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 4K | $0.00 | $0 | 17K |
| 2026-07-30 | Hansen Gwenn | Chief Scientific Officer | Sell | 4K | $23.38 | $90K | 121K |
| 2026-07-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 4K | $0.00 | $0 | 125K |
| 2026-07-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 3K | $0.00 | $0 | 122K |
| 2026-07-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 4K | $0.00 | $0 | 119K |
| 2026-07-02 | Ring Christine | Chief Legal Officer | Sell | 11K | $23.56 | $259K | 14K |
| 2026-07-02 | Ring Christine | Chief Legal Officer | Exercise or conversion | 6K | $8.72 | $50K | 25K |
| 2026-07-02 | Ring Christine | Chief Legal Officer | Exercise or conversion | 5K | $1.86 | $10K | 19K |
| 2026-06-25 | Ring Christine | Chief Legal Officer | Exercise or conversion | 13K | $7.26 | $97K | 27K |
| 2026-06-25 | Ring Christine | Chief Legal Officer | Exercise or conversion | 16K | $8.72 | $136K | 43K |
| 2026-06-25 | Ring Christine | Chief Legal Officer | Sell | 29K | $20.06 | $580K | 14K |
| 2026-06-25 | Hansen Gwenn | Chief Scientific Officer | Sell | 5K | $20.00 | $108K | 115K |
| 2026-06-02 | Ring Christine | Chief Legal Officer | Sell | 8K | $16.60 | $135K | 14K |
| 2026-06-02 | Ring Christine | Chief Legal Officer | Exercise or conversion | 3K | $1.86 | $6K | 22K |
| 2026-05-05 | van Houte Hans | Chief Financial Officer | Sell | 582 | $17.18 | $10K | 38K |
| 2026-05-05 | van Houte Hans | Chief Financial Officer | Sell | 13K | $16.58 | $223K | 38K |
| 2026-05-04 | Ring Christine | Chief Legal Officer | Sell | 8K | $16.96 | $138K | 18K |
| 2026-05-01 | Ring Christine | Chief Legal Officer | Sell | 5K | $16.76 | $90K | 26K |
| 2026-04-30 | van Houte Hans | Chief Financial Officer | Sell | 2K | $16.65 | $40K | 52K |
| 2026-04-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 3K | $0.00 | $0 | 54K |
| 2026-04-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 4K | $0.00 | $0 | 51K |
| 2026-04-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 2K | $0.00 | $0 | 47K |
| 2026-04-30 | Ring Christine | Chief Legal Officer | Sell | 3K | $16.65 | $53K | 32K |
| 2026-04-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 3K | $0.00 | $0 | 35K |
| 2026-04-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 4K | $0.00 | $0 | 32K |
| 2026-04-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 2K | $0.00 | $0 | 28K |
| 2026-04-30 | Hansen Gwenn | Chief Scientific Officer | Sell | 3K | $16.65 | $53K | 120K |
| 2026-04-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 3K | $0.00 | $0 | 124K |
| 2026-04-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 4K | $0.00 | $0 | 121K |
| 2026-04-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 2K | $0.00 | $0 | 117K |
| 2026-04-02 | Ring Christine | Chief Legal Officer | Sell | 8K | $15.24 | $124K | 26K |
| 2026-03-02 | Ring Christine | Chief Legal Officer | Sell | 8K | $15.44 | $126K | 35K |
| 2026-02-09 | Ring Christine | Chief Legal Officer | Sell | 14K | $16.66 | $238K | 43K |
| 2026-02-03 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 31K | $0.84 | $26K | 115K |
| 2026-01-30 | van Houte Hans | Chief Financial Officer | Sell | 73 | $17.37 | $1K | 45K |
| 2026-01-30 | van Houte Hans | Chief Financial Officer | Sell | 4K | $16.58 | $59K | 46K |
| 2026-01-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 3K | $0.00 | $0 | 49K |
| 2026-01-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 4K | $0.00 | $0 | 46K |
| 2026-01-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 2K | $0.00 | $0 | 42K |
| 2026-01-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 3K | $0.00 | $0 | 40K |
| 2026-01-30 | Ring Christine | Chief Legal Officer | Sell | 88 | $17.37 | $2K | 57K |
| 2026-01-30 | Ring Christine | Chief Legal Officer | Sell | 4K | $16.58 | $72K | 57K |
| 2026-01-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 3K | $0.00 | $0 | 61K |
| 2026-01-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 4K | $0.00 | $0 | 59K |
| 2026-01-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 2K | $0.00 | $0 | 55K |
| 2026-01-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 2K | $0.00 | $0 | 53K |
| 2026-01-30 | Hansen Gwenn | Chief Scientific Officer | Sell | 98 | $17.37 | $2K | 84K |
| 2026-01-30 | Hansen Gwenn | Chief Scientific Officer | Sell | 5K | $16.58 | $80K | 84K |
| 2026-01-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 3K | $0.00 | $0 | 89K |
| 2026-01-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 4K | $0.00 | $0 | 86K |
| 2026-01-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 2K | $0.00 | $0 | 82K |
| 2026-01-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 3K | $0.00 | $0 | 80K |
| 2026-01-20 | Ring Christine | Chief Legal Officer | Sell | 4K | $18.42 | $69K | 51K |
| 2026-01-20 | Ring Christine | Chief Legal Officer | Exercise or conversion | 4K | $1.86 | $7K | 55K |
| 2025-12-18 | Ring Christine | Chief Legal Officer | Sell | 200 | $18.55 | $4K | 51K |
| 2025-12-18 | Ring Christine | Chief Legal Officer | Sell | 4K | $17.87 | $64K | 51K |
| 2025-12-18 | Ring Christine | Chief Legal Officer | Exercise or conversion | 4K | $1.86 | $7K | 55K |
| 2025-11-24 | Ring Christine | Chief Legal Officer | Sell | 38K | $17.07 | $642K | 51K |
| 2025-11-24 | Ring Christine | Chief Legal Officer | Exercise or conversion | 38K | $1.86 | $70K | 88K |
| 2025-11-03 | van Houte Hans | Chief Financial Officer | Sell | 6K | $12.56 | $79K | 38K |
| 2025-10-30 | van Houte Hans | Chief Financial Officer | Sell | 3K | $12.80 | $40K | 44K |
| 2025-10-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 3K | $0.00 | $0 | 47K |
| 2025-10-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 4K | $0.00 | $0 | 44K |
| 2025-10-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 2K | $0.00 | $0 | 40K |
| 2025-10-30 | van Houte Hans | Chief Financial Officer | Exercise or conversion | 3K | $0.00 | $0 | 38K |
| 2025-10-30 | Ring Christine | Chief Legal Officer | Sell | 4K | $12.80 | $47K | 51K |
| 2025-10-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 3K | $0.00 | $0 | 55K |
| 2025-10-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 4K | $0.00 | $0 | 52K |
| 2025-10-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 2K | $0.00 | $0 | 48K |
| 2025-10-30 | Ring Christine | Chief Legal Officer | Exercise or conversion | 2K | $0.00 | $0 | 46K |
| 2025-10-30 | Hansen Gwenn | Chief Scientific Officer | Sell | 4K | $12.80 | $52K | 77K |
| 2025-10-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 3K | $0.00 | $0 | 81K |
| 2025-10-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 4K | $0.00 | $0 | 78K |
| 2025-10-30 | Hansen Gwenn | Chief Scientific Officer | Exercise or conversion | 2K | $0.00 | $0 | 74K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON20 Form 144 notices on file for NRIX worth $4.5M at the prices reported; 7 in the last 90 days worth $1.6M. Latest: JULIA GREGORY filed on 2026-10-14 to sell 22,583 shares ($529K) from 2026-10-14.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-14 | JULIA GREGORYDirector | 23K | $529K | 0.021% | 2026-10-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-10-02 | CHRISTINE RINGOfficer | 6K | $135K | 0.006% | 2026-10-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-02 | CHRISTINE RINGOfficer | 6K | $151K | 0.006% | 2026-09-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-05 | GWENN HANSENOfficer | 9K | $215K | 0.008% | 2026-08-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-04 | JOHANNES VAN HOUTEOfficer | 5K | $111K | 0.005% | 2026-08-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-04 | GWENN M HANSENOfficer | 4K | $95K | 0.004% | 2026-08-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-03 | CHRISTINE RINGOfficer | 17K | $385K | 0.016% | 2026-08-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-02 | CHRISTINE RINGOfficer | 11K | $263K | 0.011% | 2026-07-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-25 | CHRISTINE RINGOfficer | 29K | $558K | 0.028% | 2026-06-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-25 | GWENN M HANSENOfficer | 5K | $104K | 0.005% | 2026-06-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-02 | CHRISTINE RINGOfficer | 8K | $142K | 0.008% | 2026-06-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-05 | JOHANNES VAN HOUTEOfficer | 14K | $238K | 0.014% | 2026-05-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-04 | CHRISTINE RINGOfficer | 8K | $137K | 0.008% | 2026-05-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-01 | CHRISTINE RINGOfficer | 5K | $90K | 0.005% | 2026-05-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-02 | CHRISTINE RINGOfficer | 8K | $126K | 0.008% | 2026-04-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | CHRISTINE RINGOfficer | 8K | $130K | 0.008% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-09 | CHRISTINE RINGOfficer | 14K | $240K | 0.014% | 2026-02-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-18 | CHRISTINE RINGOfficer | 8K | $137K | 0.010% | 2025-12-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | CHRISTINE RINGOfficer | 38K | $630K | 0.049% | 2025-11-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-03 | JOHANNES VAN HOUTEOfficer | 6K | $81K | 0.008% | 2025-11-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON20 holders report 5% or more of NRIX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Jeremy C. Green at 8.1% of the class (8,782,256 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-23 | 13G | Joseph Edelmanindividual | 5.5M | 5.3% | 2026-09-16 |
| 2026-09-23 | 13G | Perceptive Advisors LLCinvestment adviser | 5.5M | 5.3% | 2026-09-16 |
| 2026-09-23 | 13G | Perceptive Life Sciences Master Fund, Ltd.corporation | 5.5M | 5.3% | 2026-09-16 |
| 2026-08-14 | 13G/Ano. 3 | Deep Track Biotechnology Master Fund, Ltd.corporation | 7.7M | 7.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Deep Track Capital, LPinvestment adviser, other entity | 7.7M | 7.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | David Kroinparent holding company, individual | 7.7M | 7.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 6 | Jeremy C. Greenparent holding company, individual | 8.8M | 8.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 6 | Redmile Group, LLCinvestment adviser, other entity | 8.8M | 8.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 6 | RedCo II Offshore SPV LLCnon-US institution, other entity | 3.7M | 3.5% | 2026-06-30 |
| 2026-08-14 | 13G | David Rosenparent holding company, individual | 7.2M | 7.0% | 2026-06-30 |
| 2026-08-14 | 13G | Rubric Capital Management LPinvestment adviser, partnership | 7.2M | 7.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Ryan Wilderparent holding company, individual | 8.1M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Vestal Point Capital, LPinvestment adviser, partnership | 8.1M | 7.8% | 2026-06-30 |
| 2026-08-14 | 13G | T. Rowe Price Associates, Inc.investment adviser | 5.4M | 5.3% | 2026-06-30 |
| 2026-07-31 | 13G | Vanguard Capital Managementinvestment adviser | 5.2M | 5.0% | 2026-06-30 |
| 2026-05-06 | 13G | FMR LLCparent holding company | 5.5M | 5.4% | 2026-03-31 |
| 2026-05-06 | 13G | Abigail P. Johnsonindividual | 5.5M | 5.4% | 2026-03-31 |
| 2026-04-24 | 13G/Ano. 5 | RedCo II Master Fund, L.P.partnership, non-US institution | 0 | 0.0% | 2026-04-20 |
| 2026-03-27 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 4 | Baker Bros. Advisors LPinvestment adviser, partnership | 7.5M | 7.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 7.5M | 7.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | Julian C. Bakerparent holding company, individual | 7.5M | 7.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | Felix J. Bakerparent holding company, individual | 7.5M | 7.2% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | Commodore Capital LPinvestment adviser, partnership | 3.8M | 4.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Commodore Capital Master LPpartnership | 3.8M | 4.9% | 2025-09-30 |
13F holders
Tracked managers holding NRIX at their latest 13F. JSON7 of the 30 tracked managers held NRIX at their latest 13F, $99.4M in total at quarter-end prices. ARK Investment Management is the largest at $43.5M (0.3% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| ARK Investment Management | 2026-06-30 | 1.8M | $43.5M | 0.28% | +72K |
| Citadel Advisors | 2026-06-30 | 1.5M | $35.8M | 0.00% | +133K |
| Fisher Asset Management | 2026-06-30 | 369K | $9.0M | 0.00% | -15K |
| D. E. Shaw & Co. | 2026-06-30 | 185K | $4.5M | 0.00% | -160K |
| AQR Capital Management | 2026-06-30 | 179K | $4.4M | 0.00% | +163K |
| Point72 Asset Management | 2026-06-30 | 73K | $1.8M | 0.00% | -376K |
| Millennium Management | 2026-06-30 | 21K | $507K | 0.00% | -525K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q3 FY 2026 (quarter ended 2026-08-31) Nurix Therapeutics reported revenue of $673.1M, up 8426.3% from the same quarter a year earlier, and net income of $549.8M (4.73 diluted EPS). In FY 2025 it generated -$249.5M of operating cash flow.
- Cash
- $720.2M
- Equity
- $968.3M
- Total assets
- $1.20B
- Shares outstanding
- 109,249,814
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q3 FY 2026 | 2026-08-31 | $673.1M | $549.8M | 81.7% | 4.73 |
| Q2 FY 2026 | 2026-05-31 | $9.0M | -$89.5M | -990.1% | -0.81 |
| Q1 FY 2026 | 2026-02-28 | $6.3M | -$87.2M | -1394.3% | -0.79 |
| Q4 FY 2025derived | 2025-11-30 | $13.6M | -$78.2M | -576.1% | n/a |
| Q3 FY 2025 | 2025-08-31 | $7.9M | -$86.4M | -1094.8% | -1.03 |
| Q2 FY 2025 | 2025-05-31 | $44.1M | -$43.5M | -98.7% | -0.52 |
| Q1 FY 2025 | 2025-02-28 | $18.5M | -$56.4M | -305.4% | -0.67 |
| Q4 FY 2024derived | 2024-11-30 | $13.3M | -$58.5M | -440.7% | n/a |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-11-30 | $84.0M | -$264.5M | -$249.5M | $14.0M | n/a | n/a |
| FY 2024 | 2024-11-30 | $54.5M | -$193.6M | -$172.6M | $9.3M | n/a | n/a |
| FY 2023 | 2023-11-30 | $77.0M | -$143.9M | -$81.4M | $8.4M | n/a | n/a |
| FY 2022 | 2022-11-30 | $38.6M | -$180.4M | -$159.8M | $12.2M | n/a | n/a |
| FY 2021 | 2021-11-30 | $29.8M | -$117.2M | -$84.4M | $5.7M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-08-31; shares outstanding as of 2026-09-30 from the cover page.
What this page is
Nurix Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Nurix Therapeutics (NRIX), SEC CIK 1549595, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-02.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-23.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-08-31.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-15.JSON and CSV
- Company record
- EDGAR filing index for CIK 1549595Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of NRIX is sold short?
17,657,588 shares were held short at the 2026-09-30 settlement, 9.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is NRIX's daily short volume?
On 2026-10-23, 315,198 of the 586,575 NRIX shares reported to FINRA were sold short, 53.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does NRIX have fails to deliver?
The SEC's latest file shows 47 NRIX shares failed to deliver at settlement 2026-09-02. Fails are reported per settlement date and published twice a month with a lag.
Are NRIX insiders buying or selling?
Insiders at NRIX reported 15 open-market sells worth $1.8M in the last 90 days and no open-market buys. Latest filing: Hansen Gwenn (Chief Scientific Officer) on 2026-10-15.
Have NRIX insiders filed to sell?
20 Form 144 notices on file for NRIX worth $4.5M at the prices reported; 7 in the last 90 days worth $1.6M. Latest: JULIA GREGORY filed on 2026-10-14 to sell 22,583 shares ($529K) from 2026-10-14.
Who owns 5% or more of NRIX?
20 holders report 5% or more of NRIX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Jeremy C. Green at 8.1% of the class (8,782,256 shares), filed 2026-08-14 for an event on 2026-06-30.
What did NRIX report last quarter?
In Q3 FY 2026 (quarter ended 2026-08-31) Nurix Therapeutics reported revenue of $673.1M, up 8426.3% from the same quarter a year earlier, and net income of $549.8M (4.73 diluted EPS). In FY 2025 it generated -$249.5M of operating cash flow.
Which tracked 13F managers own NRIX?
7 of the 30 tracked 13F managers held NRIX shares at their latest filing, $99.4M in all. The largest: Cathie Wood's ARK Investment Management (1.8M shares, $43.5M), Ken Griffin's Citadel Advisors (1.5M shares, $35.8M), Ken Fisher's Fisher Asset Management (369K shares, $9.0M), D. E. Shaw & Co. (185K shares, $4.5M), Cliff Asness's AQR Capital Management (179K shares, $4.4M), Steve Cohen's Point72 Asset Management (73K shares, $1.8M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.